Teva Pharmaceutical Industries said its investigational TEV ‘408 anti-interleukin-15 monoclonal antibody met the primary endpoint in an ongoing Phase 2a study involving 50 adults with celiac disease. After a single subcutaneous dose and a six-week daily gluten challenge, treatment significantly reduced gluten-induced intestinal damage at week 8 versus placebo, with a least squares mean Vh:Cd change of -0.43 versus -0.88 for placebo. TEV ‘408 also showed more favorable intestinal inflammation and gastrointestinal symptom results and was well-tolerated, with no emerging safety signals. Teva said additional analyses are underway and that it plans to present further data at a future scientific meeting. The company is also developing TEV ‘408 for vitiligo and described the asset as a potential pipeline-in-a-product opportunity across multiple diseases.